CEACAM5 and cancer: Currently, a single-arm, open-label, dose-escalating + dose-expansion clinical study (NCT05538195) was conducted to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations and preliminarily observe the study drug in CEA-positive advanced malignant tumors.